
























































MEDICINE published: 18 November 2014doi: 10.3389/fmed.2014.00044
Pretargeted imaging and radioimmunotherapy of cancer
using antibodies and bioorthogonal chemistry
Floor C. J. van deWatering1, Mark Rijpkema1, Marc Robillard 2,Wim J. G. Oyen1 and Otto C. Boerman1*
1 Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, Netherlands
2 Tagworks Pharmaceuticals, Eindhoven, Netherlands
Edited by:
Jean-Pierre Pouget, INSERM, France
Reviewed by:
Zhen Cheng, Stanford University, USA
Laurence Carroll, Imperial College, UK
*Correspondence:
Otto C. Boerman, Department of
Radiology and Nuclear Medicine,
Radboud University Medical Center,
Geert Grooteplein Zuid 10, Nijmegen
6525 GA, Netherlands
e-mail: otto.boerman@radboudumc.nl
Selective delivery of radionuclides to tumors may be accomplished using a two-step
approach, in which in the first step the tumor is pretargeted with an unlabeled antibody
construct and in the second step the tumor is targeted with a radiolabeled small molecule.
This results in a more rapid clearance of the radioactivity from normal tissues due to the
fast pharmacokinetics of the small molecule as compared to antibodies. In the last decade,
several pretargeting approaches have been tested, which have shown improved tumor-to-
background ratios and thus improved imaging and therapy as compared to directly labeled
antibodies. In this review, we will discuss the strategies and applications in (pre-)clinical
studies of pretargeting concepts based on the use of bispecific antibodies, which are capa-
ble of binding to both a target antigen and a radiolabeled peptide. So far, three generations
of the bispecific antibody-based pretargeting approach have been studied.The first clinical
studies have shown the feasibility and potential for these pretargeting systems to detect
and treat tumor lesions. However, to fully integrate the pretargeting approach in clinic,
further research should focus on the best regime and pretargeting protocol. Additionally,
recent developments in the use of bioorthogonal chemistry for pretargeting of tumors sug-
gest that this chemical pretargeting approach is an attractive alternative strategy for the
detection and treatment of tumor lesions.
Keywords: pretargeting, bispecific antibodies, tumor-associated antigen, radioimmunodetection, radioim-
munotherapy
INTRODUCTION
The use of radiolabeled monoclonal antibodies (mAbs) directed
against tumor-associated antigens to visualize, characterize,
and/or treat tumor lesions has been widely studied in preclinical
and clinical studies (1–3). After intravenous injection, the accumu-
lation of the radiolabeled mAbs in the tumor is slow due to the slow
extravasation and tissue penetration of intact antibodies. Various
physiological barriers between the circulation and the tumor cell
surface, such as the vascular endothelium, the relatively large trans-
port distances, and the high interstitial fluid pressure in tumors,
prevent the rapid accretion of the antibodies in the tumor (4). As
a result, only a small fraction of the injected activity will localize
in the tumor. Despite this inefficient targeting, in various clini-
cal settings this approach can be effective: especially radiosensitive
tumors, like Non-Hodgkin’s lymphomas,can respond to treatment
with radiolabeled anti-CD20 antibodies (5). Effective radioim-
munotherapy (RIT) requires high tumor uptake and rapid clear-
ance of radioactivity from normal tissues. Various approaches have
been investigated to improve the tumor targeting such as reducing
the circulatory half-life of the antibodies (4). Molecular engineer-
ing techniques made it possible to produce antibody formats that
clear faster from the blood. However, this is the central dilemma
in antibody targeting of tumors: on one hand, the high level of
mAb in the circulation is the driving force for the accumulation of
the mAb in the tumor; on the other hand, the clearance from nor-
mal tissues should be rapid. Therefore, innovative approaches are
needed to enhance tumor accumulation while limiting retention in
normal tissues. Pretargeting is an approach to solve this problem.
Several pretargeting systems have been developed including the
avidin/streptavidin-biotin pretargeting system (4, 6) exploiting the
extremely high binding affinity between biotin and (strept)avidin
(K d= 4× 10−14 M) (7), the DNA-complementary DNA binding
pretargeting system, which relies on the high affinity interaction
between complementary oligomers (8–11), pretargeting systems
based on the use of bispecific antibodies (bsAb), and recently a
novel pretargeting approach has been reported based on highly
selective bioorthogonal chemical reactions (12, 13). All pretar-
geting systems are promising; however, each of these approaches
has its advantages and limitations. For the avidin/streptavidin,
the most significant limitation is the immunogenicity of the pre-
targeting agents: (strept)avidin being a protein that cannot be
humanized. Additionally, the presence of endogenous biotin that
could interfere with the system and the need to use a clearing
agent to remove the residual antibody from the circulation before
administration of the radiolabeled biotin limit the application of
this system (14). For the DNA-complementary DNA binding pre-
targeting system, no immunogenic issues or complications due
to the presence of competing endogenous species are reported.
However, the oligonucleotides need to be modified to prevent
rapid degradation by DNases and/or RNases (11). The pretarget-
ing concept based on the use of bsAb directed against both a target
antigen and a radiolabeled hapten is carried out in the following
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FIGURE 1 | Schematic overview of the pretargeting strategy. First, tumors are pretargeted with bispecific antibodies (bsAb). Secondly, small radiolabeled
hapten peptide is i.v. injected and binds to the pretargeted bsAb at the tumor cells.
two steps. In the first step, the bsAb is injected. After the bsAb
has accumulated in the tumor due to the specific binding to
the tumor-associated antigen and cleared from the blood, the
radiolabeled peptide carrying the hapten is administrated. This
small molecule will be trapped in the tumor by binding to
the bsAb or cleared rapidly from the body via the kidneys. A
schematic overview of this pretargeting strategy is shown in
Figure 1. Depending on the radionuclide used this pretargeting
approach can be used to visualize, or treat tumor lesions, for
example, using 111In and 99mTc for single-photon emission com-
puted tomography (SPECT) imaging, 68Ga or 18F for positron
emission tomography (PET) imaging, or 131I, 90Y, and 177Lu for
pretargeted radioimmunotherapy (PRIT). A significant advan-
tage of this system over the biotin/avidin-based approaches is
that the primary pretargeting agent, the bsAb, can be human-
ized to reduce its immunogenicity. Additionally, the lower affinity
of the bsAb-hapten binding compared to the avidin-biotin bind-
ing results in the rapid dissociation of the bsAb from the hap-
ten in the circulation, thereby omitting the need for a clearing
agent. In the past decade, several improvements on this system
have been introduced, which resulted in a flexible universal and
efficient pretargeting system. However, the non-covalent bind-
ing between the radiolabeled hapten and the bispecific antibody
at the tumor cell surface limit the retention of the radiolabeled
hapten-peptide in the tumor. Recent developments in the use of
bioorthogonal chemistry (cf. the rapid and selective formation of
a covalent bond between the pretargeting agent and the radiola-
beled agent in vivo) are very promising and show the potential of
this system for efficient pretargeting of tumors. Thus, this chemi-
cal pretargeting system is an attractive alternative for bsAb-based
pretargeting.
In this review, we will focus on the pretargeting concept based
on the use of bsAb and additionally discuss the potential and
the limitations of this novel bioorthogonal chemistry pretargeting
approach.
BISPECIFIC ANTIBODY-BASED PRETARGETING SYSTEMS
The first studies on the use of a two-step system to target tumors
were described by Reardan et al. (15). This group used anti-
bodies against radiolabeled EDTA. This study showed that by
separating the antibody tumor targeting from radionuclide tar-
geting improved tumor-to-non-tumor ratios could be obtained
(16). These antibodies had no affinity to the tumor and accumu-
lated passively due to the enhanced permeability and retention
effect in the tumor (4, 17, 18). For specific pretargeting of tumors,
bsAb directed against both the tumor-associated antigens and the
radiolabeled agent are required.
FIRST GENERATION; ANTI-TUMOR Fab′×ANTI-CHELATE-METAL FAB′
FRAGMENTS
The first generation of bsAb for specific pretargeting methods was
chemically conjugated anti-tumor Fab′× anti-chelate-metal Fab′
fragments (6). Several preclinical studies revealed good tumor
uptake (19, 20). Stickney et al. linked the sulfhydryl groups of
Fab′ fragments of anti-CEA to those of an anti-benzyl-EDTA to
form an F(ab′)2 bifunctional antibody (19). The potential of this
anti-CEA× anti-benzyl-EDTA F(ab′)2 was evaluated in mice bear-
ing colon tumor xenografts. The anti-CEA× anti-benzyl-EDTA
Fab′× Fab′ was injected 24 h prior to the i.v. administration of
111In-labeled benzyl-EDTA. One day later, the biodistribution
revealed a tumor uptake of 18.5%ID/g, whereas the blood level
was 1.3%ID/g. A clinical study was performed to assess the use
of this approach in patients with recurrent colon carcinoma. In
14 patients, 20 of the 21 known tumor lesions were detected by
scintigraphic imaging. Additionally, nine unknown lesions were
detected of which eight could be confirmed.
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SECOND GENERATION; THE USE OF A DIVALENT RADIOLABELED
HAPTEN-PEPTIDE
The pretargeting system using anti-tumor Fab′× anti-chelate-
metal Fab′ fragments was based on monovalent binding to
the chelate–radiometal complex at the tumor. The stability of
such a complex is limited and rapid release of the radiola-
beled chelate from the tumor may occur (21). Le Dousall et al.
reported improved stability of the complex using divalent hapten-
peptide (22). In BALB/c mice i.v. injection of bsAb directed
against the lyb8.2 antigen and the hapten dinitrophenyl (DNP)
followed by either the mono [N -ε-(2,4-dinitropheny1)-l-lysyl-
diethylenetriaminepentaacetic acid (DNP-DTPA)] or divalent
(di-DNP-DTPA).
The 125I-divalent DNP derivative exhibited a significantly
higher binding as compared to the monovalent derivative to the
pretargeted cells (for monovalent 23 vs. 65%ID/g for the divalent
derivative). It was hypothesized that at the cell surface the divalent
hapten could cross-link two bsAbs thereby stabilizing not only the
binding to the bsAb but also the bsAb binding to the tumor. This
so-called affinity enhancement system (AES) improved tumor tar-
geting and retention of the radiolabeled di-hapten-peptide (20,
22). This AES was confirmed by different groups in several animal
models, in which enhanced tumor uptake and improved reten-
tion of the radiolabeled di-hapten-peptide was observed (23–28).
For example, the use of a bsAb in combination with a diva-
lent 111In-DTPA-peptide resulted in a tumor uptake of 3.5%ID/g
whereas the tumor uptake of the monovalent DTPA was 2.8%ID/g
in mice with s.c. A375 melanoma xenograft. A pronounced AES
effect was observed in nude mice with RCC xenografts using bsAb
directed against the renal cell carcinoma-associated antigen G250,
in combination with a divalent hapten-peptide, Phe–Lys(DTPA-
111In)–Tyr–Lys(DTPA-111In), 111In-di-DTPA (16). At 1 h p.i. of
the hapten, an almost 10-fold higher tumor uptake of 111In-di-
DTPA (80%ID/g) was observed as compared to the monova-
lent 111In-DTPA (9%ID/g; Figure 2). Moreover, the retention of
the radiolabel in the tumor at 72 h p.i. was significantly higher
for the 111In-di-DTPA (93± 41%ID/g) compared to 111In-DTPA
(0.9± 0.1%ID/g).
Based on the promising preclinical studies, a clinical trial
was performed to evaluate the pretargeting approach in patients
with primary colorectal cancers. In 11 patients with primary col-
orectal carcinoma tumors, anti-CEA× anti-DTPA Fab′–Fab′ anti-
body was injected followed 2–8 days later by 111In-labeled N -α-
(In-DTPA)-tyrosyl-N -ε-(In-DTPA)-lysin (111In-di-DTPA) (29).
For comparison, six patients with similar clinical status were
injected with 111In-anti-CEA F(ab′)2. At 1–4 days p.i. of 111In-
di-DTPA, the biodistribution results revealed a tumor uptake
of 1.8–17.5%ID/kg and were similar to the tumor uptake of
111In-anti-CEA F(ab′)2 (5.5–30.2%ID/kg). However, the tumor-
to-blood (T/B) and the tumor-to-liver (T/L) ratios were signifi-
cantly improved in the pretargeting approach: 7.8 vs. 4.2 and 2.8
vs. 0.8, respectively (29).
Besides using a pretargeting approach to detect tumor lesions,
the pretargeting approach was also tested to treat tumor lesions.
A clinical trial was conducted to estimate the dose delivered to
tumor targets and normal tissues using a pretargeting approach
consisting of bsAb anti-CEA× anti-DTPA and 131I-diDTPA (30).
FIGURE 2 | Biodistribution of 111In-diDTPA (A) and 111In-DTPA (B) at
1–72 h after injection of the radioactivity in nude mice with s.c. NU-12
tumors. Mice received 100 pmol of G250×DTIn1 bsAb i.v. and 3 days later
7 pmol of 111In-DTPA or 111In-diDTPA. As a reference a separate set of
nude mice with s.c. NU-12 xenografts received the directly labeled antibody
111In-DTPA-G250 (C). This research was originally published in Cancer
Research by Boerman et al. (16).
In the clinical trial patients with recurrent medullary thyroid car-
cinoma (MTC; five patients) and small-cell lung cancer (SCLC;
five patients) were pretargeted with a bsAb anti-CEA× anti-DTPA
Fab′–Fab′ (0.1–0.3 mg/kg) and 4 days later 6 nmol (5.8–9.8 mCi)
of 131I-di-DTPA was administrated. The patients were included
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based on the CEA expression as evaluated by immunohistochem-
ical analysis of the biopsy of their primary tumor. The tumor
uptake of 131I-di-DTPA and the activity dose to the tumor was
significant higher in MTC (average uptake 0.116%ID/g; dose
ranged from 4.8 to 135 cGy/mCi) than in SCLC (average uptake
0.009%ID/g; dose ranged from 1.9 to 8 cGy/mCi), indicating that
the MTC is a more suitable tumor type for PRIT. The therapeu-
tic efficacy and toxicity of PRIT with escalating doses of bsAb
anti-CEA× anti-DTPA (20–50 mg) and 4 days later followed by
131I-di-DTPA (1.48–3.7 GBq) was evaluated in 26 patients with
recurrent MTC (24). The dose-limiting toxicity was hematologic
and an activity dose of 1.78 GBq/m2 could be injected safely
in this group of patients. The maximum tumor uptake ranged
from 0.003 to 0.26%ID/g and the tumor doses ranged from 7.9
to 500 Gy/MBq (2.94–184 cGy/mCi). From the 26 patients, 17
patients were included to evaluate the tumor response. The max-
imal tolerated dose (MTD) of 48 mCi/m2 was administrated to
13 patients. A decrease in tumor mass, serum thyrocalcitonin,
and CEA levels was observed in six of the patients receiving the
MTD. The tumors that showed a response were generally small
(maximum diameter of 37 mm).
Despite the promising (pre)clinical outcomes using a divalent
hapten-peptide, the antibody dissociation rates were still higher
as compared to the high affinity pretargeted avidin–biotin com-
plex (K d= 10−14 M for biotin with streptavidin/avidin vs. 10−9 M
for most antigen–antibody complexes) (7). It was suggested that
bsAb divalency to the primary target antigen might result in
higher tumor accretion by the pretargeted divalent peptide (21).
A bsAb chemically prepared by coupling two Fab′ fragments,
one with monovalent specificity to CEA and one to 111In-DTPA
(Fab′× Fab′) was compared to bsAb with divalency to CEA. Two
divalent CEA bsAb coupled to a DTPA Fab′ fragment were com-
posed either of the whole anti-CEA IgG (IgG× Fab′) or the
anti-CEA F(ab′)2 fragment [F(ab′)2× Fab′). The antibody con-
structs differ in molecular weight resulting in different clearance
rates from the blood of which the fastest clearance is observed
with lowest molecular weight construct, Fab′× Fab′, followed by
F(ab′)2× Fab′ and slowest for IgG× Fab′. The highest uptake
and retention in the tumor was achieved using the IgG× Fab′
bsAb conjugate. However, in a pretargeting strategy, the uptake
of the 111In-di-DTPA peptide (111In-IMP-192) was highest using
F(ab′)2× Fab′ conjugate followed by Fab′× Fab′ conjugate and
lowest for IgG× Fab′. At the time of maximum tumor accretion,
the IgG× Fab′ in the blood predominantly captured the injected
hapten. As a consequence, the three- to fourfold higher tumor
accumulation of the IgG× Fab′ could not be exploited in the pre-
targeting approach. Consequently, to take full advantage of a high
uptake and retention in the tumor using a long circulating bsAb,
the accessibility of the bsAb remaining in the blood need to be
reduced by using a clearing agent (21).
The flexibility of the bsAb pretargeting system is increased using
the second generation anti-chelate bsAb as different radionuclides
can be used, for example, 111In (21, 29) for imaging and 131I for
treatment (24, 30). However, the binding affinity can be affected
by the chelated metal. For example, the affinity of the anti-DTPA
antibody, designated 734, to various radiometal labeled DTPA
varies from 10−9 M for In-DTPA to 10−3 M for Ca-DTPA (31).
Additionally, the anti-(In)DTPA had a much lower affinity for
DTPA with other radiometals such as 90Y or 177Lu. Therefore, it
appeared that imaging radionuclides require different antibodies
directed against the specific anti-chelate–metal complex than the
radionuclides of therapeutic interest.
THIRD GENERATION; BISPECIFIC F(ab′)2
ANTI-CEA×ANTI-HISTAMINE-SUCCINYL-GLYCINE
A more universal/flexible pretargeting system was developed by
using an anti-hapten antibody not directed against the chelated
radiometal, but directed against the histamine-succinyl-glycine
(HSG) hapten (22, 32, 33). The HSG hapten itself is not involved
in binding the radionuclide and thus other chelates suitable for
binding radionuclides can be added, for example, the HSG pep-
tides can be conjugated with various chelating moieties such
as DTPA, DOTA, or N3S chelates for radiolabeling with In-
111, Lu-177/Y-90, or Tc-99m/Re-188, respectively or with other
agents/moieties such as fluorophores for fluorescence imaging.
Sharkey et al. showed the potential of this system by using
the bispecific anti-CEA F(ab′)2× anti-HSG Fab in combination
with HSG peptides labeled with either 99mTc or 188Re via an
N3S chelate or with 111In, 177Lu, and 90Y via a DOTA moi-
ety (32). In nude mice with human colon tumor xenografts,
this trivalent anti-CEA× anti-HSG bsAb was injected 24–48 h
prior to the i.v. administration of the divalent radiolabeled HSG
peptides, 111In-IMP241, 177Lu-IMP241, and 99mTc-IMP243. The
tumor uptake of radiolabeled HSG peptides after pretargeting
with the bsAb was significantly higher than with the peptides
alone (for 111In-IMP241 0.03± 0.02 vs. 2.54± 1.04%ID/g, for
177Lu-IMP241 0.03± 0.01 vs. 2.59± 0.3%ID/g, and for 99mTc-
IMP243 0.1± 0.02 vs. 7.36± 3.19%ID/g). The tumor-to-normal
tissue ratio exceeded 8:1 within 3 h p.i. of the hapten-peptide.
Consequently, this provides the opportunity to use the same HSG
peptide for different purposes depending on the radionuclide
used, for example, using 111In and 99mTc-labeled HSG peptide
for SPECT imaging, 124I, 68Ga, or 18F-labeled HSG peptide for
PET imaging or 131I, 90Y, and 177Lu-labeled HSG peptide for
PRIT (32–38). Besides the flexibility of the system, Sharkey et al.
showed that the hapten–peptide structure can alter the biodistrib-
ution and clearance of the construct. The liver and kidneys uptake
of 99mTc-hapten-peptide consisting of a N3S chelate and DOTA
(IMP245) was significantly lower compared to the 99mTc-hapten-
peptide bearing only the N3S chelate whereas the tumor uptake
and retention did not change. Therefore, when less background is
essential around the kidneys and/or urinary bladder, the preferable
renal elimination can be altered to a more hepatic elimination by
modifying the hapten-peptide construct.
Further improvements were obtained using a recombinant bis-
pecific trivalent construct, hBS14, with bivalent CEA binding and
a monovalent HSG binding (39). The trivalent antibody was pro-
duced by myeloma cells transfected with hBS14-pdHL2 DNA
vector and purified to near homogeneity in a single step using
a novel HSG-based affinity chromatography system. In nude mice
bearing a CEA-expressing GW-39 human colon tumor xenograft
the efficacy of the 125I-hBS14 (0.4 nmol) in combination with the
bivalent 111In-HSG-hapten (0.04 nmol; 27 h interval), IMP241,
was evaluated. At 3 h p.i., the 111In-IMP241 tumor uptake was
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FIGURE 3 | Schematic representation of how a trivalent bispecific
antibody is formed by the DNL method. Component A links a
cysteine-modified dimerization and docking domain (DDD) to a Fab of an
anti-tumor antibody, which results in spontaneous formation of component
A2. Component B links an anchoring domain to a Fab of an anti-hapten
antibody. The AD is modified with cysteine on each end. AD will naturally
“dock” with the DDD when components A and B are mixed, which brings
the two molecules together in a well-defined orientation and also results in
disulfide bonds across the two proteins. This research was originally
published in Goldenberg et al. (42).
19.1± 8.7% ID/g and the blood levels were only 0.25± 0.08% ID/g
corresponding with a tumor-to-blood ratio of 83± 44% ID/g.
Technology that exploits fusing two hybridoma Ab-producing
cells using quadroma technology did not produce adequate yields
in mammalian cell cultures. Therefore, a new strategy capable of
preparing a trivalent bsAb was developed. Humanized trivalent
Fab bsAb constructs were produced at a higher yield by the dock-
and-lock (DNL) technology. The DNL technology is based on the
natural association between protein kinase A (PKA; cyclic AMP-
dependent protein kinase) and A-kinase anchoring proteins. The
regulatory subunit of PKA and the anchoring domain of the inter-
active A-kinase anchoring protein are both attached to a biological
entity. The dimeric sequence attached to the anti-tumor F(ab)2 has
high affinity for the sequence attached to the anti-hapten Fab, the
so-called docking. The stabilization of the trivalent bispecific anti-
body construct, the so-called locking, is secured by the placement
of cysteine residues on four locations within the construct result-
ing in the formation of disulfide bridges (40–42). A schematic
overview of the DNL technology is shown in Figure 3.
Using the DNL technology, several recombinant humanized
bsAbs with a divalent antigen specificity and with a monovalent
specificity to HSG were produced including an anti-CEA bsAb
(TF2) (43, 44), an anti-Trop2 (TF12) (45), an anti-CD20 (46), and
an anti-MUC1 (47) bsAb.
An effective detection and treatment of tumor lesions using a
pretargeting system is best illustrated by the work done on TF2.
The ability to detect small micrometastatic human colon cancer
nodels (<0.3 mm in diameter) in the lungs of nude mice using
this system was evaluated and compared to 18F-FDG-PET imag-
ing and to TF6, an irrelevant anti-CD22-based bsAb. The tumors
were first pretargeted with TF2 and 21–24 h later the 124I or 131I
radiolabeled hapten-peptides were injected at a bsAb:hapten molar
ratio of 10:1. The TF2-pretargeted tumors in the lungs could be
localized at 1.5 h p.i. of radiolabeled HSG peptide whereas the
peptide alone, TF6, or 18F-FDG failed. This showed the high
potential of the system for sensitive and specific imaging of tumor
lesions.
The specificity of the TF2 based pretargeting system was fur-
ther evaluated using di-HSG peptides radiolabeled with 68Ga,
a positron emitting radionuclide with a more suitable half-life
(68 min) for pretargeted imaging purposes than 124I (4.2 days)
(48). Nude mice were s.c. implanted with CEA-expressing LS174T
human colonic tumor, a CEA-negative tumor, or an inflamma-
tion was induced in the thigh muscle. The mice were first i.v.
injected with bsAb anti-CEA× anti-HSG and after 16 h followed
by 68Ga-IMP288. At 1 h p.i., a high specific uptake of 68Ga-
IMP288 was observed in the tumor (10.7± 3.6%ID/g), whereas
the uptake of 68Ga-IMP288 in normal tissues, in CEA-negative
tumors and inflamed muscle was low (Figure 4). In contrast,
18F-FDG localized efficiently in the tumor, however, also in the
inflamed tissue and in a number of normal tissues including
liver, spleen, and intestines. The specificity of the pretargeted
immuno-PET using TF2 and 68Ga-IMP288 was confirmed in mice
with small intraperitoneal xenografts (49). All intra-abdominal
tumors lesions >~4 mm and even a few lesions as small as
~2 mm were detected. In line with the previous study, the 18F-
FDG uptake in all the present tumors was sufficient, however,
also an uptake was observed in various normal tissues such as the
intestines.
To evaluate the use of the TF2 and 177Lu-IMP288 in PRIT,
the therapeutic efficacy and toxicity of the system was evalu-
ated in mice with s.c. LS174T tumors (50). The median survival
of mice treated with 1, 2, or 3 cycles of PRIT was 24, 45, and
65 days, respectively, whereas in the untreated mice the median
survival was 13 days. Additionally, PRIT effectively delayed the
tumor growth with limited hematologic toxicity, indicating that
PRIT using TF2 and 177Lu-IMP288 might be an effective treatment
against colon cancer. Furthermore, the biodistribution of 111In-
IMP288 and 177Lu-IMP288 in mice with intraperitoneal LS174T
tumors was identical as observed by ex vivo counting as well
as by pretargeted immuno-SPECT imaging (51). This indicates
that pretargeted immuno-SPECT with TF2 and 111In-IMP288 can
be used for the non-invasive monitoring of the therapeutic effi-
cacy of PRIT with TF2 and 177Lu-IMP288 in mice with LS174T
lesions.
The preclinical pretargeting studies using TF2 in combination
with radiolabeled di-HSG peptides indicated that PRIT can induce
tumor growth inhibition. Therefore in the feasibility, safety and
therapeutic efficacy of TF2/Lu-177-IMP288 for the treatment of
CEA-expressing tumor lesions was investigated in a first-in-man
phase I study in patients with advanced colorectal carcinoma. Four
dose schedules in cohorts of five patients were evaluated (52).
First, the effect of the time interval between administration of
TF2 (75 mg) and IMP288 (100µg) was evaluated: 5 days (cohort
1) and 1 day (cohort 2). Additionally, the effect of a higher bsAb
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FIGURE 4 | PET/CT images of a BALB/c nude mouse with a s.c. LS174T
tumor on the right hind leg (arrow) and an inflammation in the left thigh
muscle (arrowhead), which received 18F-FDG and, 1 day later, 6.0 nmol TF2
and 68Ga-IMP288 (0.25 nmol) with a 16-h interval. The animal was imaged
1 h after 18F-FDG and 68Ga-IMP288 injections. The panel shows the
three-dimensional volume rendering the pretargeted immuno-PET scan (A)
and the FDG-PET scan (B), and the transverse sections of the tumor region
of the pretargeted immuno-PET scan (C) and the FDG-PET scan (D). This
research was originally published in Schoffelen et al. (48, 50).
dose (150 mg TF2, 1-day interval, 100µg IMP288, cohort 3) and
a lower IMP288 dose (75 mg TF2, 1-day interval, 25µg IMP288,
cohort 4) was evaluated. Reducing the time interval and lowering
the IMP288 dose resulted in improved tumor targeting. Although
it is reported that higher bsAb doses results in improved tumor
uptake of the radiolabeled hapten (48, 50), no such observations
were found using twofold increase of TF2 dose. Co-localization
of almost all 18F-FDG positive tumors and hapten-peptide with
SPECT was observed (Figure 5). Using a high TF2 dose and a
low IMP288 peptide dose rapid targeting of tumors was observed,
although wash-out of the tumor was observed after 24 h. The
patients could tolerate 7.4 GBq of 177Lu-IMP288 without expe-
riencing dose-limited toxicity, even though some patients (8 out
of 20 patients) experienced some level of hematologic toxicity. The
TF2 bsAb induced human anti-human antibodies (HAHA) in 11
out of 21 patients. Most likely, the best PRIT regime will be a frac-
tionated multi-dose treatment regimen (e.g., multiple cycles) as
observed in preclinical pretargeting experiments (50) and recent
clinical trials using 90Y-labeled antibodies in combination with
gemcitabine (53). However, further clinical studies regarding the
pretargeting conditions and protocol are needed.
FIGURE 5 |The SPECT/CT image (A), acquired 24 h after injection of
111In-IMP288 (185 MBq, 25µg), pretargeted with 75 mgTF2 (1-day
interval), in a 38-year-old patient (cohort 4), shows very clear tumor
targeting of an axillary lymph-node metastasis, with very low
concentrations of radioactivity in normal tissues. Corresponding
contrast-enhanced CT scan and a fused FDG-PET/CT scan are shown
[(B,C), respectively]. The primary colon tumor (50 cm ab ano) also shows
highly specific tumor targeting in the SPECT image (D), confirmed by the
CT scan and FDG-PET/CT [(E,F), respectively], with non-specific FDG
uptake in the ascending colon. This research was originally published in
Schoffelen et al. (52).
A DIFFERENT APPROACH; PRETARGETING BASED ON
BIOORTHOGONAL CHEMISTRY
The combination of chemistry and biology has resulted in many
innovations and has contributed to our understanding of many
biological processes. Nevertheless, many biomolecules including
lipids,glycans,and nucleic acids as well as various posttranslational
modifications cannot be monitored with genetically encoded
reporters as manipulations can interfere with the structure and
function of the molecules or the molecules are not genetically
encoded. Therefore, new methods were investigated to covalently
modify biomolecules in vivo. This has led to the discovery of
bioorthogonal reactions to detect, track, or visualize various bio-
molecules. Using bioorthogonal chemistry, as defined by Bertozzi
et al., reactions can occur inside a living organism, which do not
interfere or cross-react with naturally occurring functionalities, are
reactive under mild and physiological conditions and should not
induce cellular toxicity (54). Over the years, several bioorthogo-
nal chemical ligation strategies have been developed including the
tetrazine ligation, Staudinger ligation, oxime/hydrazone forma-
tion from aldehydes and ketones, and quadricyclane ligation [for
reviews on these bioorthogonal chemical reactions see in Ref. (13,
55, 56)]. The archetypical bioorthogonal reaction is the copper-
catalyzed 1,3-dipolar Huisgen“click”cycloaddition between azides
and alkynes (55). Using this click chemistry, units are joined with
heteroatom links (C-X-C) in a modular, rapid, and easy manner
without the generation of toxic byproducts (57). The selectivity
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and flexibility as well as the bioorthogonality and speed of click
chemistry make it an ideal method for the creation of radiophar-
maceuticals, especially 18F-radiolabeled peptides (58). The bind-
ing of a radiolabeled probe to the tumor-targeted antibody might
also be obtained using bioorthogonal reactions. In general, this
chemical approach of pretargeting is less likely to be immunogenic
and could provide a universal approach for tagging and in vivo
tracking of Abs. However, the need for a copper catalyst in coupling
of azide and terminal alkyne to generate a triazole limits the use of
the 1,3-Huisgen cycloaddition reaction in biological systems due to
the toxicity of copper in vivo.Various bioorthogonal reactions have
been developed that do not need the presence of a Cu catalyst. For
example, copper-free click chemistry can be achieved via the relief
of strain (strain-promoted azide-alkyne cycloadditions, SPAAC).
Alternatively, Blackman et al. reported the very fast reaction kinet-
ics and in vitro bioorthogonality of the inverse-electron-demand
Diels–Alder (IEDDA) reaction between trans-cyclooctene (TCO)
and electron deficient tetrazines (59). Subsequently, Devaraj et al.
tagged the anti-EGFR antibody cetuximab with trans-cyclooctene
succinimidyl carbonate and combined with a fluorescent tetrazine
probe was able to target A549 cancer cells in serum at 37°C (60). A
schematic overview depicting the use of TCO-modified mAb and
radiolabeled tetrazine to (pre)target tumors through the IEDDA
reaction is shown in Figure 6. The first in vivo proof-of-concept
study by Rossin et al. using a chemical pretargeting approach based
on the Diels–Alder components demonstrated that the system
could manage the more demanding conditions in vivo, includ-
ing low reagent concentrations and short reaction time, and the
prolonged residence time and required in vivo stability for the
TCO tag (61). In mice bearing a colon-cancer xenografts, TCO-
modified anti-TAG72 mAb CC49 (CC49-TCO) was administrated
and 1 day later followed by 111In-labeled-DOTA-tetrazine (111In-
tetrazine) at a 1:25 molar ratio. Three hours p.i. of 111In-tetrazine,
SPECT imaging clearly delineated the tumor with a tumor uptake
of 4.2%ID/g and a tumor-to-muscle (T/M) ratio of 13.1, whereas
the tumor uptake of 111In-tetrazine and tumor-to-muscle ratio
pretargeted with unmodified CC49 or an irrelevant TCO-modified
Ab were 0.3 and 0.5%ID/g or 1.0 and 2.1%ID/g, respectively
(Figure 7).
Zeglis et al. demonstrated that the in vivo click method-
ology is able to delineate tumors with PET (62). Nude mice
with s.c. SW1222 colorectal cancer xenografts were i.v. adminis-
trated with TCO-modified A33 Ab (100µg) followed 24 h later by
64Cu-NOTA-tetrazine (10.2–12.0 MBq) or with the directly radi-
olabeled Ab 64Cu-NOTA-A33 (10.2–12 MBq) or 89Zr-DFO-A33
(10.2–12.0 MBq). Despite the higher tumor accumulation of the
directly labeled antibodies at 24 h p.i, the pretargeting approach
resulted in comparable PET images and tumor-to-muscle ratios
(Figure 8).The dose delivered to normal tissues using this pretar-
geting approach was calculated, indicating that the non-targeted
tissues received a significant lower dose when a pretargeting
approach (0.0124 mSv/MBq) was used compared to the directly
labeled Abs, 64Cu-NOTA-A33, and 89Zr-DFO-A33 (0.0359 and
0.4162 mSv/MBq, respectively).
The fast reaction kinetics [k2= 13,090 M−1s−1 (60)] of the
IEDDA reaction between the trans-cycloctene and tetrazines are
very promising, however, are still significantly lower compared
to the association constants of the non-covalent high affinity
interactions used in humans (5× 105 up to 7.5× 107 M−1s−1).
In addition, Rossin et al. reported that the TCO can be deac-
tivated through isomerization to the unreactive cis-cyclooctene
(CCO) isomer via copper-containing proteins (e.g., transcuprein,
mouse serum albumin, ceruloplasmin) (61). TCO tags that are
linked to the antibody through an axial substituent afforded a
marked increase of the reactivity (61). In conjunction, the sta-
bility of the TCO tag could be improved by removal of the PEG
linker between the TCO and the lysine residue on the Ab, increas-
ing the steric hindrance on the TCO thus hampering interaction
with serum protein-bound copper. The increased reactivity (up to
k2= 2.7× 105 M−1s−1 in PBS (61) and improved stability of the
IEDDA between a tetrazine and TCO-tagged antibody resulted
in an improved tumor-to-blood ratio (61). Devaraj et al. (64)
reported that the in vivo reaction yield of a moderately reactive
IEDDA system (k2= 6× 103 M−1s−1 in PBS) could be improved
FIGURE 6 | Schematic overview of tumor pretargeting by using the inverse-electron-demand Diels–Alder reaction. This research was originally published
in Rossin et al. (60).

























































van de Watering et al. Pretargeting of cancer
by altering the pharmacokinetics of the radiolabeled probe by
polymer conjugation (64). In mice with LS174T xenografts TCO-
tagged A33 antibody (30µg) was administrated and followed 24 h
later by the 18F-labeled, dextran-based tetrazine probe (30µg;
150µCi). PET imaging 3 h p.i. of the 18F-labeled tracer revealed a
FIGURE 7 | SPECT/CT imaging of mice bearing colon carcinoma
xenografts: posterior projections of mice preinjected with (A)
CC49-TCO followed 1 day later by 111In-DOTA-tetrazine (1:25, 42 MBq),
(B) CC49 followed 1 day later by 111In-DOTA-tetrazine (1:25, 20 MBq), (C)
irrelevant Ab (Rtx-TCO; 100µg) followed 1 day later by
111In-DOTA-tetrazine (1:25, 50 MBq), (D–F) single transverse slices
(2 mm) passing through the tumors in (A–C). This research was originally
published in Rossin et al. (60).
significant higher tumor accumulation in TCO-tagged antibody
pretargeted mice compared to mice pretargeted with Ab lack-
ing TCO. However, the tumor-to-blood ratio still remained low
due to the relative high amount of free-circulating CC49-TCO.
For effective tumor targeting, a clearing agent was developed
that could clear the TCO-tagged antibody from the circulation
prior to administration of the radiolabeled tetrazine (61). In mice
with LS174T tumor xenografts, 125I-CC49-TCO was injected after
which a single or double dose (30 h or 30 and 48 h after mAb injec-
tion) of the clearing agent, followed 2 h later by 177Lu-tetrazine.
Three hours p.i., the blood level of 125I-CC49-TCO was lowest
after the double dose of clearing agent (0.19± 0.04%ID/g), fol-
lowed by the single dose (1.16± 0.43%ID/g) and highest in the
group without clearing agent injection (8.47± 4.12%ID/g). The
biodistribution of 177Lu-tetrazine showed that the elimination
of the free CC49-TCO in combination with a reduced amount
of tetrazine (from 17 to 6.7 nmol) significantly improved the
tumor uptake from 3.12± 0.87%ID/g (60) to 7.45± 1.46%ID/g
for the single dose and to 6.13± 1.09%ID/g for the double dose
of clearing agent. Both single as well as the double dose approach
significantly increased the tumor-to-muscle and tumor-to-blood
ratios compared to the previous approach without clearing agent.
In fact, a 125-fold improvement of the tumor-to-blood ratio at
3 h after tetrazine injection was achieved with a double dose of
clearing agent. Corresponding mouse dosimetry experiments sug-
gested that at MTD for bone marrow (dose-limiting organ for
both approaches), this should allow for an eightfold higher tumor
dose than is possible with non-pretargeted RIT. The estimated
dose to the tumor in mice with directly 177Lu-labeled CC49 is
significantly higher compared to the pretargeted approach using
CC49-TCO and 177Lu-Tz (9573 vs. 479 mGy/MBq). However, also
the normal tissues receive high doses, for example, the bone mar-
row receive 1136 mGy/MBq, whereas in the pretargeting approach
the bone marrow dose is 7 mGy/MBq. Subsequently, this sys-
tem was further improved by modifying the pharmacokinetics
of the tagged antibody and by increasing the stability of the tag.
The use of a more hydrophilic tag with an increased in vivo tag
stability (t 1/2= 10 days) afforded a slower clearing CC49-TCO
conjugate with increased tumor targeting, resulting in a 50%
increased tumor uptake and T/NT ratios of the tetrazine probe
(65). So far, the reaction of TCO with 1,2,4,5-tetrazines is the
FIGURE 8 | PET images of 64Cu-Tz-Bn-NOTA/A33-TCO pretargeting strategy, 64Cu-NOTA-A33 and 89Zr-DFO-A33.Transverse (top) and coronal (bottom)
planar images intersect the center of the tumors. This research was originally published in Zeglis et al. (63).
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fastest bioorthogonal reaction (61). While others were unsuccess-
ful in enlisting the slower SPAAC for antibody-based pretargeting
in mice (62), Lee et al. reported a pretargeting system consisting
of aza-dibenzocyclooctynes modified mesoporous silica nanopar-
ticles in combination with 18F-azide and achieved tumor uptake
in mice, possibly due to the high loading capacity of the meso-
porous particles (66). Further work is required to establish whether
the fastest cyclooctynes enable efficient SPAAC-based pretargeting
with antibodies as well.
CONCLUSION
Clinical studies revealed that the pretargeting approach based on
bsAb directed against a tumor-associated antigen and against HSG
in combination with radiolabeled (divalent) peptides contain-
ing the HSG residue resulted in high contrast images. There-
fore, the use of this pretargeting system is very promising for
non-invasive imaging of tumors before, during, and after ther-
apy. Additionally, pretargeted RIT using this system is capable
to inhibit tumor growth with minor toxicity. However, to fully
develop this pretargeting approach in the clinic research should
focus on the best regime and protocol. Although several com-
parative studies between a pretargeting approach and directly
radiolabeled antibodies have been performed, further quantita-
tive comparative studies are needed to evaluate the potential of the
pretargeted imaging and therapy. Furthermore, preclinical stud-
ies using bioorthogonal chemical pretargeting based on the inverse
Diels–Alder cycloaddition revealed that tumors can be imaged and
treated with this new approach. This approach is still being fur-
ther optimized and clinical studies are warranted to determine the
potential of this new strategy.
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